Make the profile of
Ibex Medical Analytics yours.

Company description

Ibex Medical Analytics is an AI-powered diagnostic solutions company founded in 2016 and headquartered in the life sciences technology space. The company's mission is to transform pathology by ensuring that every patient receives an accurate, timely, and personalized cancer diagnosis. Developed by pathologists for pathologists, Ibex serves the world's leading physicians, healthcare organizations, and diagnostic solution providers. Today, Ibex is recognized as the most widely deployed artificial intelligence platform in pathology, with its solutions actively used in live clinical rollouts across the globe.

Every day, Ibex's field-proven AI platform helps pathologists detect cancer and a broad range of diagnostic features across multiple tissue types, raising physician confidence, streamlining diagnostic workflows, and enabling better clinical outcomes for patients worldwide. The platform's algorithms have been trained on rich datasets extracted from over 10 million slides sourced from multiple pathology institutes, leveraging deep learning technologies developed by teams of expert pathologists.

Core AI Platform Capabilities

• Detection of cancer and more than one hundred other diagnostic features across multiple tissue types
• Clinically proven accuracy with enhanced efficiency and improved user experience for pathologists
• Multiple AI algorithms trained by expert pathologists using advanced deep learning technologies
• Developed from datasets comprising over 10 million slides from multiple pathology institutes
• Deployed worldwide for detecting breast, prostate, and gastric cancer across multiple diagnostic workflows
• Provides unprecedented diagnostic insights and predictions at the speed of technology

Key Products and Solutions

• Ibex Breast: An AI solution for breast cancer diagnosis that delivers near-perfect concordance with consensus pathologist diagnoses, providing accurate insights on invasive carcinoma types, nuclear grading of in situ carcinomas, and additional diagnostic features, as validated in studies at Institut Curie, Paris
• Ibex Prostate: An AI solution for prostate cancer diagnosis covering Gleason grading, tumor sizing, detection of perineural invasion, and other clinically relevant features, validated with area-under-the-curve performance close to near-perfect in peer-reviewed studies conducted at the University of Michigan and University of Pittsburgh Medical Center
• Gastric Cancer Detection: AI-powered analysis extending to gastric tissue types as part of the broader multi-cancer diagnostic platform

Clinical Impact and Outcomes

• Faster cancer diagnosis and reduced turnaround times across the diagnostic pathway
• Enhanced diagnostic quality and greater physician confidence in making correct and reproducible tissue diagnoses
• Ability to detect small foci of cancer, including higher-grade cancers that may be very small and easily missed
• Functions as an AI-powered second opinion, acting as a companion for pathologists reviewing large volumes of diagnostic material
• Prospective quality control capabilities that help pathologists identify the right areas of cancer
• Optimized workflows that improve productivity across the entire cancer diagnostic pathway
• Supports more personalized, high-impact cancer care for patients

Validation and Clinical Endorsements

• Validated by leading academic medical centers including Institut Curie (Paris), Betsi Cadwaladr University Health Board (Wales), University of Tennessee Health Science Center, University of Michigan, and University of Pittsburgh Medical Center
• Advisory board includes prominent pathologists from Brigham and Women's Hospital, Moffitt Cancer Center, University Hospitals Cleveland Medical Center, and other leading institutions
• Endorsed by expert pathologists who highlight the platform's ability to improve diagnostic confidence, reproducibility, and quality of care

Funding and Investors

• Raised $55 million in a Series C funding round to drive global adoption of AI for cancer diagnosis
• The Series C round was led by 83North and included Sienna Venture Capital, Octopus Ventures, aMoon Fund, Planven Entrepreneur Ventures, and Dell Technologies Capital
• Backed by a strong investor base supporting the company's global expansion and clinical deployment strategy

Company Background and Leadership

• Founded in 2016 with a focus on AI-powered pathology diagnostics
• Leadership team includes CEO Yair Heller, Co-founder and President Joseph Mossel, Co-founder and CTO Chaim Linhart PhD, and Chief Medical Officer Judith Sandbank MD
• Additional senior leadership spans commercial, operations, engineering, product, regulatory, and clinical functions
• Advisory board comprises internationally recognized pathologists and oncology experts from top-tier academic medical centers and research institutions

Ibex Medical Analytics continues to expand its global footprint as the leading deployed AI platform in pathology, partnering with health systems, diagnostic providers, and physicians committed to delivering higher-quality, more targeted cancer care to patients around the world.

AI-generated · replace with your own

Software attributed to Ibex Medical Analytics

• Ibex ProstateView
• Ibex Breast SuiteView
• Ibex GastricView

Edit all with premium access